New Daiichi Sankyo CEO Confident Of Resolving Ranbaxy U.S. Issues
This article was originally published in PharmAsia News
Executive Summary
Daiichi Sankyo's new CEO expressed confidence the company would resolve issues with the U.S. FDA about operations at its Indian subsidiary, generics giant Ranbaxy Laboratories